IPM Take
Personalised surgical care should consider the conditions patients bring into the operating theatre, not only the disease requiring surgery. This trial investigated a defined group: adults with existing dry eye undergoing pars plana vitrectomy. Its findings suggest a possible role for targeted adjunctive treatment, while leaving uncertainty about the clinical importance, durability and safety of the observed benefit. For preventive care pathways, the immediate opportunity is to investigate how baseline ocular-surface assessment can guide treatment without turning preliminary evidence into universal prescribing.
Executive Summary
A single-centre randomised trial in China enrolled 163 adults with pre-existing dry eye disease undergoing pars plana vitrectomy, a retinal surgical procedure. Participants received either 0.05% ciclosporin A plus 0.1% sodium hyaluronate or sodium hyaluronate alone for three months. The adjusted between-group difference in change in the Ocular Surface Disease Index symptom score was −5.29 points at three months, favouring combination treatment, with a 95% confidence interval of −6.53 to −4.05. Exploratory analyses also found differences over time in several objective ocular-surface measures. The authors described symptom improvement as modest and called for larger, double-masked trials. Retrospective trial registration and limited detail in the abstract warrant additional scrutiny before clinical implementation.
Why it matters
- Clinicians: The study suggests a possible adjunctive approach for patients who already have dry eyes when undergoing vitrectomy. It does not establish that all retinal surgery patients should receive ciclosporin or that the treatment improves retinal surgical outcomes.
- Public authorities: The findings offer a research question for integrated surgical pathways: whether identifying and treating pre-existing ocular-surface disease produces patient-important benefits that justify additional treatment and follow-up.
- Patients and advocates: Comfort and dry eye symptoms are relevant outcomes alongside the retinal condition requiring surgery. However, the study reported a modest average benefit, not a guarantee of improvement for every patient.
Retinal surgery addresses disease inside the eye. A new trial asks whether care around that operation should also target an existing problem on its surface.
Researchers in China studied adults with dry eye disease who were undergoing pars plana vitrectomy, or PPV, a retinal surgical procedure. They investigated whether adding topical ciclosporin A to a lubricant improved symptoms and ocular-surface measurements compared with the lubricant alone.
Published online in Ophthalmology and Therapy on 16 November 2026, the study provides an early signal for a targeted approach. Its findings also illustrate why statistical improvement should not be confused with a settled treatment recommendation.
A defined patient group
The prospective, single-centre randomised trial enrolled 163 adults with pre-existing dry eye. Eighty-two were allocated to 0.05% ciclosporin A plus 0.1% sodium hyaluronate, while 81 received 0.1% sodium hyaluronate alone. Treatment was studied over three months.
This design matters because the comparison was not treatment versus no care. Both groups received sodium hyaluronate; the trial assessed the additional effect of ciclosporin within that treatment setting.
The population was also deliberately specific. These were not unselected surgical patients or people who first developed dry eye after their operation. Any interpretation should remain anchored to adults who already had dry eyes when undergoing PPV.
That distinction limits the scope of the finding, but gives it a potentially useful personalised-care angle: testing an intervention in people with an identified baseline condition.
What improved and by how much
The primary outcome was changed from baseline to three months in the Ocular Surface Disease Index, or OSDI, a questionnaire used to assess dry eye symptoms and their effects.
The adjusted difference in score change between groups was −5.29 points, favouring combination treatment. The 95% confidence interval ranged from −6.53 to −4.05, and the result was statistically significant. A separate analysis using complete cases produced a similar estimate of −5.19 points.
The authors characterised the symptom improvement as modest. That wording is important: the result describes an average difference between groups, not the proportion of patients who experienced a substantial improvement.
The abstract does not report a responder analysis showing how many participants reached a prespecified, patient-important improvement threshold. It therefore cannot establish the likelihood that an individual patient will notice a worthwhile benefit.
Symptoms and examination findings
The researchers also assessed several secondary outcomes: non-invasive tear break-up time, the Schirmer I test, tear meniscus height and corneal fluorescein staining. These measures examine different aspects of tear-film stability, tear production or the ocular surface.
Exploratory analyses identified statistically significant group-by-time interactions for all four measures. In practical terms, this indicates that their trajectories differed between treatment groups during follow-up.
However, the abstract does not provide the numerical between-group effects for these outcomes. Their statistical significance should not be translated into claims of large improvements or normalisation.
Nor did the reported primary outcome concern retinal anatomy or visual recovery. The findings should therefore not be presented as evidence that ciclosporin improves the success of vitrectomy itself. The supported conclusion concerns dry eye symptoms and ocular-surface outcomes.
Personalised medicine opportunity
The opportunity is to connect baseline assessment with a clearly defined treatment question.
Rather than assuming that every person undergoing retinal surgery has the same supportive-care needs, this trial focused on patients with an existing ocular-surface condition. That is consistent with a personalised approach, although it does not establish which patients within that group benefit most.
The abstract does not identify a validated selection rule based on dry eye severity, inflammatory features or other characteristics. It also does not establish whether the observed benefit would vary across different reasons for vitrectomy.
For clinicians and service designers, those are useful next research questions. Future studies could test whether baseline characteristics predict benefit and whether additional treatment improves outcomes that patients consider meaningful.
This is targeted-care research, not yet a validated precision-prescribing strategy.
Looking ahead
Several limitations require attention. The study was conducted at one centre, follow-up lasted three months, and the trial was registered retrospectively. The authors explicitly called for confirmation in larger, double-masked trials.
Retrospective registration makes it particularly important to compare the final report with the protocol and registration record before publication or implementation. The abstract also does not provide sufficient adverse-event information to support a complete safety assessment.
Further research should establish the size and durability of patient-important benefit, tolerability, treatment burden and applicability to other surgical settings. Until then, the findings support cautious investigation rather than routine adoption.
Personalised surgical care means recognising the whole eye- and demanding reliable evidence for each additional treatment.

